Novanta Inc (1GSN) - Total Liabilities

Latest as of September 2025: €704.34 Million EUR ≈ $823.44 Million USD

Based on the latest financial reports, Novanta Inc (1GSN) has total liabilities worth €704.34 Million EUR (≈ $823.44 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Novanta Inc (1GSN) long-term investment share to see how much of total assets are deployed in long-term investments.

Novanta Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how Novanta Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Novanta Inc asset portfolio.

Novanta Inc Competitors by Total Liabilities

The table below lists competitors of Novanta Inc ranked by their total liabilities.

Company Country Total Liabilities
Choice Hotels International Inc
NYSE:CHH
USA $2.85 Billion
Premier Energies Limited
NSE:PREMIERENE
India Rs65.35 Billion
KONINKLIJKE VOP.UNSP.ADR
F:VPK
Germany €3.54 Billion
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
India Rs11.91 Billion
Hongda
SHG:600331
China CN¥587.78 Million
Union Bank of Taiwan Pref
TW:2838A
Taiwan NT$970.36 Billion
Acm Research Inc
NASDAQ:ACMR
USA $982.43 Million
Page Industries Limited
NSE:PAGEIND
India Rs13.77 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Novanta Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1GSN net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.88 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.47 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novanta Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novanta Inc (2015–2024)

The table below shows the annual total liabilities of Novanta Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 €642.81 Million
≈ $751.52 Million
+16.33%
2023-12-31 €552.60 Million
≈ $646.04 Million
-16.73%
2022-12-31 €663.63 Million
≈ $775.85 Million
-6.08%
2021-12-31 €706.59 Million
≈ $826.08 Million
+81.94%
2020-12-31 €388.37 Million
≈ $454.05 Million
-14.18%
2019-12-31 €452.56 Million
≈ $529.09 Million
+28.82%
2018-12-31 €351.32 Million
≈ $410.73 Million
-15.38%
2017-12-31 €415.16 Million
≈ $485.36 Million
+148.94%
2016-12-31 €166.77 Million
≈ $194.97 Million
-2.67%
2015-12-31 €171.34 Million
≈ $200.32 Million
--

About Novanta Inc

F:1GSN Germany Scientific & Technical Instruments
Market Cap
$4.85 Billion
€4.15 Billion EUR
Market Cap Rank
#3891 Global
#700 in Germany
Share Price
€116.00
Change (1 day)
+0.00%
52-Week Range
€84.50 - €150.00
All Time High
€171.00
About

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets las… Read more